Articles tagged with Disease Progression
A new gene therapy approach using the neuroprotective protein SynCav1 has shown promising results in slowing down ALS disease progression and increasing life span in rodent models. The treatment preserved spinal cord motor neurons and extended longevity in mice, with similar effects observed in a rat model of ALS.
Researchers developed a non-invasive ocular imaging method to detect flavoprotein fluorescence in the eye, indicating mitochondrial oxidative stress. This technique may predict glaucoma progression earlier than current methods, with similar sensitivity to visual field changes.
A study published in Nature Physics reveals that specialized cell movement may explain the progression of cancer and cystic fibrosis. Cells with ruffled edges sense viscosity and adapt to increase their speed, moving faster through mucus than blood. This discovery sheds light on disease mechanisms and potential treatments.
Researchers found clots in small venous and arterial blood vessels in normal-looking skin from patients with severe COVID-19, distinguishable from other forms of respiratory illness. Antiviral proteins and interferon-induced inflammatory proteins were also detected, associated with disease severity.
A MedUni Vienna study team has identified a specific subtype of macrophages as a protective function against fibrosis in non-alcoholic fatty liver disease. TREM2-positive macrophages have been shown to prevent fat accumulation, inflammatory processes and progression to liver fibrosis.
A novel staging framework assesses Huntington's Disease progression and enables early-stage clinical trials of drugs. The HD-ISS groups patients by biological, clinical, and functional characteristics, allowing researchers to evaluate therapeutics in the earliest stages of disease.
A novel BRAF inhibitor, C1a, has been developed to cross the blood-brain barrier and treat melanoma brain metastasis. The study found that C1a triggered robust responses in patient-derived models and outperformed approved BRAF inhibitors, achieving significant increases in survival rates.
A new review analyzes the efficacy of current non-invasive methods for assessing non-alcoholic fatty liver disease (NAFLD) and associated conditions. Blood-based biomarker tests and imaging methods are explored, with some showing promise in early diagnosis and staging liver disorders.
A review of scientific evidence concludes that diet has little impact on the progression of osteoarthritis and rheumatoid arthritis. While a healthy diet brings other health benefits, the impact on these diseases is small and not clinically meaningful.
Researchers developed an algorithm to classify patients into disease subtypes based on molecular changes, enabling more targeted treatments. The tool has shown potential in a study on non-alcoholic fatty liver disease, identifying lipid biomarkers for disease progression.
Breast cancer cells accumulate intracellular lipid droplets in acidic environments, leading to poor outcomes and disease progression. Targeting the acid-sensing receptor OGR1 may inhibit stress responses and cell growth.
Researchers from Indiana University School of Medicine identify a key brain receptor that leads to a loss of neurons and synaptic structure in Alzheimer's disease models. The study found that targeting this receptor could prevent or delay the onset of Alzheimer's-related neuropsychiatric symptoms and cognitive deficits.
A blood test can predict which patients with COVID-19 pneumonia are most likely to become severely ill. Researchers found that levels of certain host proteins increased or decreased at different stages of hospitalization, providing insight into the progression of disease.
A study examined the frequency of FDA's extrapolation of pivotal trial data to approved indications, finding it occurred in 45% of cases. This practice may lead to different clinical results in real-world use compared to trials.
Researchers have identified a key protein molecule that plays a major role in the accumulation of brain cholesterol, triggering Alzheimer's disease. The peptide inhibitor ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheimer's disease models.
Researchers at WEHI have discovered a new accordion-like trigger crucial to gene silencing, which expands our understanding of how genes are switched on and off in the womb. The finding offers a new way to potentially harness gene silencing to treat diseases like cancer and congenital disorders.
Scientists at University of Illinois and Mie University develop monoclonal antibodies to prevent lung cell death in mouse models of idiopathic pulmonary fibrosis and acute respiratory disease syndrome. Non-invasive diagnostic tools also presented could aid in predicting disease progression and identifying patients at risk.
Researchers have found that immune checkpoint inhibitors like pembrolizumab can slow disease progression in patients with high-grade meningiomas. The study showed that nearly half of all patients were alive and without evidence of disease progression for at least 6 months after treatment.
A study by Nagoya City University researchers found that patients with persistent postural-perceptual dizziness (PPPD) often exhibit exacerbating factors shortly after onset, worsening symptoms. These factors include upright posture, movement, and visual stimulation.
A study published in Nature Medicine defines distinct subgroups of stem cells that expand during MDS treatment and drive resistance. Researchers found that targeting these specific stem cell classes with therapies like venetoclax may improve outcomes for patients with disease progression.
Researchers found a relationship between regionalized fibrosis in the left ventricle and mitral valve prolapse disease, suggesting potential benefits from earlier surgical intervention. Advanced fibrosis could be added to traditional markers for mitral valve repair.
Researchers have identified how IL-36 cytokines instruct proinflammatory CD4+ T cells to accumulate in the inflamed intestine, worsening disease. This discovery offers fresh insights into targeting these proteins as a new therapeutic option for childhood IBD patients.
A Rutgers study found that hospital patients with repeated negative RT-PCR tests but exhibiting COVID-19 signs and/or symptoms were half as likely to receive treatment as those who tested positive. The study suggests that clinicians should not solely rely on RT-PCR tests for COVID-19 diagnosis.
A new study on the Symbol Digit Modalities Test (SDMT) has found that group-level scores lack significance on an individual level. The normative study recommends a higher cut-off score for SDMT to accurately assess changes over time and predict disease progression.
The collaboration aims to create an interoperable global data ecosystem for rare diseases, accelerating the development of new therapies. This partnership benefits patients, regulators, advocacy stakeholders, researchers, and industry, while expanding C-Path's global capabilities in collaborating on methodologies and technologies.
Researchers developed a new 'Easy-BILAG' tool to measure lupus disease progression, enabling accurate and consistent assessments in 91.3% of cases. The single-page document uses color-coding to make assessment more user-friendly, reducing completion time from 80 minutes to under an hour.
Scientists have mapped the tau interactome, showing that mutant tau impacts mitochondria function in human neurons. The study also reveals a mechanism for tau release from neurons and its binding to mitochondrial proteins, which may inform future studies on preventing diseased tau spread.
A recent University of Waterloo study shows that wearable biosensors can provide insight into patterns of health-related behaviour and disease symptoms, enabling remote monitoring of people with complex health conditions. The study found that participants were willing to wear multi-sensor devices for extended periods, highlighting the ...
A recent study found that patients with hormone receptor-positive breast cancer who experience rising ESR1 mutations before disease progression can benefit from an early switch to fulvestrant plus palbociclib. This approach yields a statistically and clinically significant gain in progression-free survival, potentially justifying its a...
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
Researchers developed an AI-powered system to model disease progression in patients as they age. The model assesses metabolic and cardiovascular biomarkers to calculate health status and disease risks across a patient's lifespan.
Researchers found that cerebral palsy patients with low muscle mass often have inaccurately calculated kidney function, leading to missed diagnoses of advanced kidney disease. This association increases the risk of cardiovascular disease and mortality in this population.
Researchers have developed a 3D cell culturing platform that allows study of lung fibroblasts and their microenvironment, enabling measurement of cell behaviors and microenvironment changes involved in IPF disease progression. The system's versatility enables personalized medicine and potential applications in studying other diseases.
A new study has identified the CCR2 gene as a key player in the progression of type 1 diabetes. The research found that lower blood levels of CCL-2, a ligand for CCR2, were associated with increased immune cell recruitment to the pancreas, leading to islet cell destruction.
Using next-generation sequencing, researchers identified four major regulatory pathways and specific molecular effectors behind COVID-19 symptoms. The study may pave the way for a more personalized approach to diagnosis and treatment.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A new pilot study reveals a prostate cancer urine test can identify men with intermediate-risk disease, allowing them to opt for active surveillance instead of immediate treatment. The test assesses the amount of aggressive cancer in the prostate without needing a biopsy.
A research team at TUM has discovered that the protein TIMP1 is associated with a significantly higher risk of liver metastasis and death in male patients, particularly those with pancreatic, colon, and melanoma cancers. This finding may lead to improved diagnosis and targeted therapy options for men.
Researchers will investigate hidden signs of brain damage in REM behavior disorder, aiming to identify biomarkers that predict impending neurological disease. The goal is to delay the onset or prevent dementia or Parkinsonism through clinical trials.
A new USC study reveals that gaps in income, education, and access to care contribute to poorer outcomes for people of color with multiple sclerosis and other autoimmune diseases. The review shows significant inequities in accessing healthcare, leading to diagnostic delays and underuse of services.
A recent study published in Frontiers in Immunology found that opioids can control gut immune responses, reduce colonic inflammation, and even promote the growth of regulatory T cells. The findings suggest that KNT-127 could be a promising therapeutic option for inflammatory bowel disease.
Researchers developed a non-toxic, small-molecule probe that provides real-time visualization of disease progression, overcoming limitations of MRI and PET imaging. The probe binds copper ions and detects dysregulated levels, accurately identifying Wilson's disease and other maladies.
A study by Massachusetts General Hospital researchers disproves the idea that increasing brain urate levels can slow Parkinson's disease progression. The SURE-PD3 trial showed no therapeutic benefit to inosine treatment, which raises urate levels, and an increased rate of kidney stones among those treated.
A new analytics platform, RDCA-DAP, will be launched to accelerate rare disease treatment innovation by hosting and standardizing rare diseases data. The platform is expected to empower patients and families to drive innovation in the field.
Researchers discovered a protein called CTRP9 associated with pulmonary function in scleroderma patients with interstitial lung disease. Patients with higher CTRP9 levels developed more severe lung disease, while low levels were linked to preserved function. The study suggests CTRP9 could help predict treatment needs for these patients.
Researchers at Wayne State University are developing new strategies to assess appropriate treatments of peripheral nerve diseases using MRI biomarkers. The study focuses on nerve MRI methods that can directly image pathology within nerves, offering valuable information on disease progression and improving treatment evaluation.
Researchers from UNC School of Medicine discovered that MUC5AC is more reliably associated with COPD manifestation than another mucus protein, revealing a possible biomarker for disease initiation and prognosis. Elevated levels of MUC5AC in non-smokers who developed COPD suggest it could predict disease progression.
Researchers found that analyzing local networks within brain regions provides superior results to traditional fiber tract connectivity approaches for predicting disease progression and surgery outcomes in epilepsy patients.
Researchers aim to characterize sIBM disease progression and explore biomarkers associated with the disease to design more effective clinical trials. The study will enroll 150 subjects and investigate differences in disease phenotype and disease progression, including muscle pathology.
Researchers integrated gait data and machine learning to monitor and predict MS-related gait issues, detecting differences in gait patterns between participants. The study identified a butterfly diagram feature associated with critical neurological functions.
For global success, vaccines must prevent all three: infection, disease progression, and transmission. The authors emphasize prioritizing vulnerable populations and healthcare workers before the wider population.
African American men with low-risk prostate cancer treated under active surveillance have a higher risk of disease progression and mortality compared to non-African American patients. The study's findings suggest that racial disparities exist in the clinical outcomes of prostate cancer treatment with active surveillance.
Researchers at KIST found that retinal neural signals from electric stimulation are altered depending on disease progression in mice affected by outer retinal degeneration. This study suggests guidelines for patient selection of retinal prostheses, improving performance and perception of artificial vision.
A new modeling study suggests that the number of infection-initiating viral variants is primarily determined by how long the source partner has been infected. The risk for multiple-founder variant transfer during sexual HIV exposure is nearly doubled during the first three months of the source partner's infection.
A research team has identified a powerful self-corrective mechanism within synapses that slows down disease progression in animal models of ALS. This mechanism is activated by neurodegeneration and acts to keep the synapse between nerve and muscle working correctly, even though the disease process has already begun to nibble away at it.
Researchers found epigenetic differences between brain hemispheres linked to variations in gene activity, making one side more vulnerable to neurological diseases. These findings could lead to new therapeutic strategies for treating Parkinson's and other neurological disorders.
Researchers at Carnegie Mellon University developed a new way to identify patients likely to return to the hospital, aiming to reduce future readmissions. The study found three distinct trajectories of readmission progression and identified high-risk patient groups, enabling early intervention and targeted care.
A new study uses AI to analyze blood samples from 1969 patients with Alzheimer's and Huntington's disease, detecting molecular patterns specific to these diseases. The algorithm reveals chronological changes in gene expression over decades, offering a long-term view of molecular changes underlying neurodegeneration.
A study found that cluster headache attacks exhibit a dynamic circadian and seasonal pattern, with changes in the attack timing throughout the disease course. Patients with more lifetime bouts showed a less variable pattern compared to those without circadian rhythmicity.
A new study at UCSF used brain maps to predict FTD progression by analyzing connected brain networks, offering insights into the disease's spread and potential clinical tools. The research suggests that individualized predictions can be made based on neural network maps, which could lead to more effective treatment development.